Intensity Therapeutics officer acquires 3,688 ESPP shares

INTENSITY THERAPEUTICS, INC.

Accepted by SEC EDGAR 07/01/2026 - 04:09 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

INTENSITY THERAPEUTICS, INC. Principal Accounting Officer John M. Wesolowski acquired 3,688 shares of common stock on an exempt basis through the company’s Amended and Restated 2024 Employee Stock Purchase Plan. The shares were purchased at $3.485 each, bringing his direct holdings to 7,102 shares.

Under the plan, the purchase price equaled 85% of the closing price of the common stock on June 30, 2026. All share amounts reported reflect a 1-for-25 reverse split of the company’s common stock that became effective on February 18, 2026.

Insider Trade Summary

Grant/Award: 3,688 shares

Grant/Award 1 txn

Insider Wesolowski John M

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.0001 Par Value	3,688	$3.485	$13K

Holdings After Transaction: Common Stock, $0.0001 Par Value — 7,102 shares (Direct)

Holdings Before and After: Common Stock, $0.0001 Par Value, 3,414 to 7,102 shares (Direct)

Footnotes (3)

1. F1. The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).
2. F2. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2026.
3. F3. On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split.

Key Figures

Shares acquired: 3,688 shares Purchase price: $3.485 per share Holdings after transaction: 7,102 shares +1 more

4 metrics

Shares acquired 3,688 shares Common stock acquired through 2024 ESPP on June 30, 2026

Purchase price $3.485 per share ESPP purchase price equal to 85% of June 30, 2026 close

Holdings after transaction 7,102 shares Direct ownership after ESPP acquisition, post-split

Reverse split ratio 1-for-25 Common stock reverse split effective February 18, 2026

Key Terms

Amended and Restated 2024 Employee Stock Purchase Plan, Rule 16b-3(c), Rule 16b-3(d), reverse split, +1 more

5 terms

Amended and Restated 2024 Employee Stock Purchase Plan financial

"the acquisition of shares under the Issuer's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP)"

Rule 16b-3(c) regulatory

"in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d)"

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

Rule 16b-3(d) regulatory

"in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d)"

Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.

reverse split financial

"the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock"

A reverse split is when a company reduces the number of its outstanding shares by combining several existing shares into one new share, so the price per share rises proportionally while the company’s overall value stays the same. Investors care because it can make a stock appear more respectable or meet exchange rules — like turning many small coins into a single larger bill — but it can also signal financial trouble and often affects trading liquidity and investor perception.

Principal Accounting Officer financial

"Wesolowski John M, Principal Accounting Officer"

The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Intensity Therapeutics (INTS) report for John M. Wesolowski?

Intensity Therapeutics reported that Principal Accounting Officer John M. Wesolowski acquired 3,688 shares of common stock through the company’s 2024 Employee Stock Purchase Plan. This exempt, plan-based acquisition increased his direct ownership to 7,102 shares after the transaction, reflecting participation in the employee equity program.

How many Intensity Therapeutics (INTS) shares does John M. Wesolowski hold after this Form 4?

After the reported transaction, John M. Wesolowski directly holds 7,102 shares of Intensity Therapeutics common stock. This total includes the 3,688 shares acquired through the Amended and Restated 2024 Employee Stock Purchase Plan and reflects the company’s 1-for-25 reverse stock split adjustments.

At what price were the Intensity Therapeutics (INTS) ESPP shares acquired in this filing?

The 3,688 shares were acquired at $3.485 per share under the company’s Employee Stock Purchase Plan. According to the plan, the purchase price equaled 85% of the closing price of Intensity Therapeutics common stock on June 30, 2026, providing a plan-defined discount.

What is the nature of John M. Wesolowski’s Intensity Therapeutics (INTS) share acquisition?

The acquisition is a compensation-related, exempt transaction under the Amended and Restated 2024 Employee Stock Purchase Plan. It is characterized as a grant, award, or other acquisition under Rule 16b-3(c) and Rule 16b-3(d), rather than an open-market purchase or discretionary trading activity.

How did the 1-for-25 reverse split affect Intensity Therapeutics (INTS) share counts in this Form 4?

On February 18, 2026, Intensity Therapeutics completed a 1-for-25 reverse split of its common stock. The company states that all share amounts reported for John M. Wesolowski, including holdings and plan acquisitions, have been adjusted to reflect this reverse split and related equity award adjustments.

Is the Intensity Therapeutics (INTS) Form 4 transaction an open-market trade?

No. The transaction reflects shares acquired under the Amended and Restated 2024 Employee Stock Purchase Plan in an exempt transaction. The filing specifies that the acquisition is exempt under Rule 16b-3(c) and Rule 16b-3(d), distinguishing it from open-market buying or selling activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wesolowski John M

(Last) (First) (Middle)

C/O INTENSITY THERAPEUTICS, INC.

1 ENTERPRISE DRIVE, SUITE 430

(Street)

SHELTON CONNECTICUT 06484

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTENSITY THERAPEUTICS, INC. [ INTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.0001 Par Value	06/30/2026		A(1)	V	3,688	A	$3.485(2)	7,102(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).

2. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2026.

3. On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split.

Remarks:

	/s/ John M. Wesolowski	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)